A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i> -Mutated Myeloid Malignancies
Curtis A. Lachowiez(Oregon Health & Science University), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Tomoyuki Tanaka(Jikei University School of Medicine), Sven Turkalj(University of Oxford), Prithviraj Bose(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Dzifa Y. Duose(The University of Texas MD Anderson Cancer Center), Hidetaka Uryu(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Marlise R. Luskin(Dana-Farber Cancer Institute), Rebecca S. Tidwell(The University of Texas MD Anderson Cancer Center), George D. Tippett(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Yi June Kim(The University of Texas MD Anderson Cancer Center), Zhihong Zeng(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Koichi Takahashi(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Sanam Loghavi(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Niels Asger Jakobsen(University of Oxford), Paresh Vyas(University of Oxford), Lucia Masárová(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center)
Cited by 122
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k